Ipca Labs board approves merger of Krebs Biochemicals

Nclt Scheme FiledStrategic Transactions View source PDF

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+5.4%1-day move

₹1619.90

prior close

₹1618.30

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.1+0.8+1.2+2.1+5.4+4.8+6.3+9.6+9.9+8.9+13.0———

Up moveDown movePending

AI summary

Ipca Labs board approved merger of Krebs Biochemicals & Industries into itself under a scheme of amalgamation. No cash consideration; share swap ratio is 7 Ipca shares of Re.1 each for every 200 Krebs shares of Rs.10 each. Ipca FY26 total income was Rs.7,431 crore versus Krebs at Rs.26 crore. Krebs makes fermentation-based APIs that Ipca currently sources from it, so the deal secures supply. It is a related party transaction done at arm's length. Promoter holding will dip marginally from 44.72% to 44.66%.

Likely market impact

Small related-party merger secures critical API supply chain with minimal dilution. No open offer triggered. Promoter stake dips marginally.